Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AB, Abilify, Absent, addressing, adefovir, adjunctive, Agglomerated, aggressive, Alkeran, Almirall, amiodarone, antibody, antifungal, antiplatelet, antipsychotic, API, araC, arose, assistance, AstraZeneca, Biodesign, Biovitrum, bisulfate, borrowed, brand, BVF, canine, captisol, carcinoma, carfilzomib, catastrophic, CDK, Cerenia, China, Chinese, Chiva, clopidogrel, complicated, concurrent, contemplated, contraceptive, contraindicated, coordinating, Cork, cyclodextrin, cydex, cytarabine, damage, deplete, developmental, Diagnostic, dipivoxil, dissolved, dissolving, DMF, dosage, doubt, epilepsy, erosion, establishedin, Euro, exacerbated, expcted, expedited, fact, family, FarmaCiencia, fast, faster, fifty, figure, fire, Fosphenytoin, GBG, Genaera, Geodon, grossed, growing, HCC, HCV, hepatitic, hepatocellular, HepB, HepC, Hepsera, Hovione, illustrated, IM, incapacitated, incomplete, infusion, ingredient, intention, interleukin, intermediate, intervention, intramuscular, JNK, judgement, JVR, kidney, KU, Labour, lamattina, lean, lender, Lisbon, Macau, main, majeure, MedImmune, melanoma, melphalan, merit, metabolite, midst, migraine, Ministry, missing, monetary, monotherapy, morphology, myeloma, nausea, Nexterone, noncommercial, notified, novation, onset, Onyx, opportunity, Orange, orphan, outlicensed, outlicensing, outsource, overcome, palliative, PCI, perception, Pharmaceuticalsfor, Pharmascience, PLAVIX, PMEA, Poltack, Portuguese, Prism, prohibited, prohibitively, propylene, Proteolix, Proximagen, purity, qualification, reconstitution, reformulation, refractory, replication, reverted, Roberson, rolling, SA, saline, SCH, simple, simultaneously, sixty, solid, solubility, solution, solvency, solvent, spectrum, spent, splenectomized, split, sterility, steroid, strict, strong, structure, sued, supplier, Swedish, Tanaproget, tartrate, thought, today, Topamax, topiramate, tornado, transplant, tumor, twenty, uncured, undergone, undisclosed, unexpected, unpredictable, unsuitable, unusually, unwilling, upcoming, Valude, vast, Venenum, vfend, voriconazole, vulnerable, wave, Welfare, zone
Removed:
Abbott, abuse, adriamycin, advancing, advisory, AG, aim, al, Alexander, alleged, amounting, appeal, approvable, approximate, approximation, Aprela, Aranesp, assay, Avenue, Bailment, Baker, Bank, banking, Barney, billion, Biopharmaceutique, Bioventure, Boston, Bristol, broader, build, built, call, Canadian, cancer, Cassidy, Chancery, Chase, Chen, collect, combine, Commonwealth, communication, conform, convene, convenience, cooperate, counsel, Crane, decision, declaratory, departing, deposited, desired, detailing, dismissal, Dorsey, Dr, drawn, Du, Dziewanowska, EITF, element, Eli, employed, employment, enforcement, enrichment, EPO, Eprex, escrowed, estimable, exclusively, Execchoice, exploit, exposed, field, FIN, Financiere, formal, functional, GAAP, Gerald, Grand, guide, Hematology, Hirsch, hot, ifosfamide, Imperial, incidence, informed, infrastructure, Innovatech, insignificance, Institutional, interim, Jean, Josefsen, JP, Kft, Knight, leader, led, Lehman, Leon, Lilly, loaned, Lockup, Loretta, lp, Ltee, MAA, Maier, Marathon, marrow, Martin, Master, Meglasson, menopausal, meruit, metabolic, mimetic, modern, molecular, Montreal, Morgan, negotiation, noncontrolling, Nonqualified, noted, obesity, Offshore, Oliver, opioid, oppose, Ordinary, organization, Pacific, par, Pasteur, Paul, penetration, placebo, Pledge, pledged, PREMARIN, Procrit, Promissory, promote, quantum, ratably, recombinant, recover, red, Reed, refunded, regimen, relief, Reorganization, repaid, repay, retail, reviewing, revised, Robert, Robinson, Royal, secured, Seidman, Separation, sharing, Shoreline, showed, smaller, Smith, Societe, Sofinov, stiffer, studied, substantially, Surgical, symptomatic, targeted, testosterone, thirty, Tod, toSergio, translation, Turi, ultra, unconditional, unjust, unknown, USL, variable, Venture, Whitney, wholesale, wind, Zofia
Filing tables
Filing exhibits
- 10-K Annual report
- 10.100 Captisol Supply Agreement
- 10.101 1ST Amendment to Captisol Supply Agreement
- 10.102 2ND Amendment to Captisol Supply Agreement
- 10.103 3RD Amendment to Captisol Supply Agreement
- 10.104 4TH Amendment to Captisol Supply Agreement
- 10.105 License Agreement
- 10.106 First Amendment to License Agreement
- 10.107 Second Amendment to License Agreement
- 10.108 Exclusive License Agreement
- 10.109 Nonexclusive License Agreement
- 10.110 Addendum to Nonexclusive License Agreement
- 10.111 Acknowledgement Agreement
- 10.112 License Agreement
- 10.113 Amendment to License Agreement
- 10.114 Supply Agreement
- 21.1 Subsidiaries of Registrant
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification by Principal Executive Officer
- 31.2 Certification by Principal Financial Officer
- 32.1 Certification by Principal Executive Officer
- 32.2 Certification by Principal Financial Officer
Related press release
LGND similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our reports dated March 3, 2011 with respect to the consolidated financial statements, schedule, and internal control over financial reporting included in the Annual Report of Ligand Pharmaceuticals Incorporated on Form 10-K for the year ended December 31, 2010. We hereby consent to the incorporation by reference of said reports in the Registration Statements of Ligand Pharmaceuticals, Incorporated on Forms S-8 (File No. 333-160132, effective June 22, 2009 and File No. 333-131029, effective June 18, 2007).
/s/ GRANT THORNTON LLP
San Diego, California
March 3, 2011